Guide
USP <2750> Readiness: Compendial Manufacturing Practices for Dietary Supplements Above 21 CFR 111
USP General Chapter <2750> Manufacturing Practices for Dietary Supplements is the United States Pharmacopeia's compendial chapter setting best-practice manufacturing standards for dietary supplements. Unlike 21 CFR 111, which is the FDA legal minimum, <2750> is a voluntary best-practice framework — but for products labelled with USP marks (USP Verified, USP-NF), for clinical-trial supplements, and for products positioned in the practitioner or professional channel, <2750> compliance is the operating expectation. Paired with the USP Dietary Supplement Verified Programme, which audits sites against <2750> and tests products against USP compendial specifications, the chapter has become the de facto practitioner-grade quality benchmark. This guide maps <2750> scope, its relationship to 21 CFR 111, and the operating posture required to claim USP alignment.
Start free trial Free trial, no credit card, onboard in days, not months.
What <2750> covers — compendial best practice, not legal minimum
USP General Chapter <2750> applies the principles of pharmaceutical manufacturing GMP to dietary supplements, calibrated for the supplement context. It covers personnel qualification and training, premises and equipment (design, qualification, cleaning, calibration), control of components and contact materials (identity, purity, strength, composition with explicit reference to USP-NF monographs where they exist for the ingredient), control of operations (master manufacturing records, batch production records, in-process controls), quality control unit responsibilities, finished-product testing and release, holding and distribution (including reserve samples), returned and salvaged supplements, complaints and records. Critically, <2750> integrates with the related general chapters: <2040> Disintegration and Dissolution, <2091> Weight Variation, <2750> for the production system itself, and the analytical chapters (<231>, <232>, <233> for heavy metals; <61>, <62>, <2021>, <2022> for microbiology).
The gap from 21 CFR 111 to <2750> — where the compendial bar sits higher
21 CFR 111 sets the FDA legal minimum: documented procedures, identity testing of components, master and batch production records, finished-product specifications. <2750> sits above 21 CFR 111 in several specific places. (1) Ingredient testing — <2750> expects testing against USP-NF monograph specifications where they exist, not just supplier COA acceptance. (2) Equipment qualification — explicit IQ/OQ/PQ documentation following the principles applied to pharmaceutical manufacturing. (3) Stability — formal stability programme generating data to support the labelled shelf life, with stability-indicating analytical methods. (4) Out-of-specification investigations — the chapter aligns with USP <1010> Analytical Data Interpretation and the pharmaceutical OOS framework. (5) Reserve sample retention — explicit retention period and conditions tied to expiry plus a year. (6) Cleaning validation — validated, not just verified.
USP Dietary Supplement Verified — the certification that operationalises <2750>
The USP Dietary Supplement Verified Programme is USP's voluntary product verification offering. Verification covers four elements: (1) product testing of the labelled SKU against USP compendial methods for identity, strength, composition, contaminants (heavy metals, pesticide residues, microbial), and disintegration where applicable; (2) on-site audit of the manufacturing facility against USP <2750>; (3) document review of master records and batch records for the verified product; (4) ongoing surveillance with annual audits and periodic product re-testing. Verified products carry the USP Verified mark on the label — heavily recognised by practitioners, pharmacists and health-conscious consumers, and a competitive differentiator on the shelf next to non-verified products. The Verified programme is paid (annual fees per site and per product) and the bar is meaningfully above 21 CFR 111.
Where <2750> matters beyond the Verified mark — clinical trials and practitioner channels
Outside the Verified mark itself, <2750> shows up as a contractual or programme requirement in several adjacent channels. (1) Clinical trial supplements — IRB-approved trials investigating supplement efficacy increasingly require the investigational product to be manufactured to <2750> or equivalent pharmaceutical GMP, because the trial's internal validity depends on product consistency. (2) Practitioner-channel brands (sold through naturopaths, integrative medicine practitioners, functional medicine clinics) routinely market <2750> alignment as the quality story. (3) Sports certification programmes (NSF Certified for Sport, Informed-Sport) layer banned-substance screening on top of a <2750>-equivalent manufacturing baseline. (4) Hospital and long-term-care supplement formularies use <2750> alignment as a procurement filter.
A 150-day path to USP <2750> alignment (Verified-ready)
Days 1-25: gap assessment of the live operation against <2750>, with explicit mapping to the related general chapters (<231>/<232>/<233>, <61>/<62>, <1010>, <1058>, <1224>). Days 26-60: USP-NF monograph linkage on every active ingredient and excipient, equipment IQ/OQ/PQ record refresh, cleaning validation. Days 61-95: stability programme stand-up with stability-indicating methods, OOS investigation procedure aligned to USP <1010>, reserve sample inventory. Days 96-120: internal audit against the <2750> control set, corrective actions on findings. Days 121-140: USP Verified product testing (if pursuing the mark) or readiness for practitioner-channel quality-claim substantiation. Days 141-150: USP on-site audit (Verified path) or commercial positioning launch.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
USP-NF monograph linkage and compendial test methods
Ingredient ID tied to USP monograph, QC release to compendial method.
USP Verified status and audit register
Verified-product list, surveillance schedule, findings register.
OOS investigation aligned to USP <1010>
OOS as a controlled record, not 'retest until passes'.
Industries this hits hardest
Frequently asked
Is USP <2750> required by the FDA?
No. The FDA legal minimum is 21 CFR 111. <2750> is a USP compendial chapter — voluntary best practice. Compliance becomes operative when the product is labelled with USP marks (USP Verified, USP-NF), when it is investigational supply for a clinical trial, or when the brand commits to <2750> alignment in the practitioner channel or in a procurement contract.
What is the difference between USP Verified and NSF/ANSI 455-2?
Both are third-party-audited supplement quality schemes operating above 21 CFR 111. USP Verified is the United States Pharmacopeia programme — facility audit against USP <2750> plus product testing against USP compendial methods, with the USP Verified mark on the label. NSF/ANSI 455-2 is the ANSI-accredited consensus GMP standard certified by NSF, UL, SGS and others — strongly favoured by major mass-market retailers. Many brands hold both for different channels.
Do I need to follow USP monographs for every ingredient?
Under <2750>, where a USP-NF monograph exists for an ingredient, the chapter expects testing against that monograph's specifications. Where no monograph exists (many botanicals, novel ingredients), the manufacturer establishes and justifies its own specifications using accepted analytical methods. The USP Dietary Supplement Compendium consolidates the monographs and is the working reference.
Can a contract manufacturer take their site to <2750> alignment for one brand?
Yes, and it is common. The <2750>-aligned controls are facility-wide once established (equipment qualification, cleaning validation, QC release procedures, MMR/BPR discipline). A CMO running a mixed customer base typically operates the whole site to <2750> alignment for all customers once the investment is made, with USP Verified status applied per-product per-customer.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- 10 CFR 35 medical use readiness — NRC licensing for radiopharmaceuticals
- 21 CFR 111 Readiness: Dietary Supplement cGMP Subparts E & F
- 21 CFR 211 Drug cGMP Readiness Guide
- 21 CFR 212 PET drug cGMP readiness — FDA inspection playbook
- 21 CFR 589 BSE / Ruminant Feed Ban Readiness Guide
- 21 CFR 820 to ISO 13485 Mapping Guide (Including QMSR Harmonisation)
Spot something off? .